Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001737287-25-000020
Filing Date
2025-02-05
Accepted
2025-02-05 16:16:37
Documents
1
Period of Report
2025-02-03

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1738790190.html 4  
1 FORM 4 wk-form4_1738790190.xml 4 3541
  Complete submission text file 0001737287-25-000020.txt   4995
Mailing Address BIOMIMETIC THERAPEUTICS, INC. 389 NICHOL MILL LANE FRANKLIN TN 37067
Business Address
Douglas Earl Martin (Reporting) CIK: 0001362155 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 25593521

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)